Department of Internal Medicine, Pusan National University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan, 49241, Republic of Korea.
Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea.
J Cancer Res Clin Oncol. 2024 Sep 4;150(9):409. doi: 10.1007/s00432-024-05931-y.
Invasive mucinous adenocarcinoma (IMA) of the lungs is a rare subtype of lung adenocarcinoma with a limited understanding of its prognosis, particularly in advanced stages. This study aimed to assess the prognosis of patients with advanced IMA by focusing on treatment modalities.
This single-center retrospective study evaluated 33 patients with IMAs diagnosed with advanced-stage disease or disease progression after curative treatment between 2011 and 2021. The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS). OS and PFS were calculated from the date of the diagnosis of advanced IMA.
The study cohort included 13 patients at the initial advanced stage and 20 patients who progressed after curative treatment. Treatment modalities included conventional chemotherapy in 24 patients (72.7%), targeted therapy in seven (21.2%), immunotherapy in 13 (39.4%), and local ablative therapy (LAT) in 13 (39.4%). The median OS was 32 months (95% confidence interval [CI], 2.9-61.0), with LAT significantly associated with improved OS compared to non-LAT treatment (not reached vs. 11.3 months, p = 0.001). However, there was no significant difference in OS based on conventional chemotherapy (p = 0.396), targeted therapy (p = 0.655), or immunotherapy (p = 0.992). In multivariate analysis, LAT remained an independent prognostic factor for OS (hazard ratio, 0.125; 95% CI, 0.026-0.608; p = 0.01). PFS was 8.6 months (95% CI, 3.6-13.7), with no significant differences observed among the treatment modalities.
Our findings suggest that LAT may provide favorable survival outcomes in patients with advanced IMA.
肺浸润性黏液腺癌（IMA）是一种罕见的肺腺癌亚型，对其预后，特别是晚期预后的了解有限。本研究旨在通过关注治疗方式来评估晚期 IMA 患者的预后。
这是一项单中心回顾性研究，评估了 2011 年至 2021 年间诊断为晚期或根治性治疗后进展的 33 例 IMA 患者。主要结局是总生存期（OS），次要结局是无进展生存期（PFS）。OS 和 PFS 从晚期 IMA 诊断日期开始计算。
研究队列包括 13 例初诊晚期患者和 20 例根治性治疗后进展患者。治疗方式包括 24 例（72.7%）常规化疗、7 例（21.2%）靶向治疗、13 例（39.4%）免疫治疗和 13 例（39.4%）局部消融治疗（LAT）。中位 OS 为 32 个月（95%置信区间 [CI]，2.9-61.0），LAT 与非 LAT 治疗相比，OS 显著改善（未达到 vs. 11.3 个月，p=0.001）。然而，常规化疗（p=0.396）、靶向治疗（p=0.655）或免疫治疗（p=0.992）之间的 OS 无显著差异。多因素分析显示，LAT 仍是 OS 的独立预后因素（风险比，0.125；95%CI，0.026-0.608；p=0.01）。PFS 为 8.6 个月（95%CI，3.6-13.7），各治疗方式之间无显著差异。
我们的研究结果表明，LAT 可能为晚期 IMA 患者提供有利的生存结果。
